Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

TILDRAKIZUMAB-ASMN: 1,621 Adverse Event Reports & Safety Profile

Visibly Younger Skin in Weeks

Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.

Discover Synevra
1,621
Total FAERS Reports
92 (5.7%)
Deaths Reported
69
Hospitalizations
1,621
As Primary/Secondary Suspect
6
Life-Threatening
2
Disabilities
Prescription
Status

FDA Application: 761067 ·

First Report: 20150728 · Latest Report: 20250916

What Are the Most Common TILDRAKIZUMAB-ASMN Side Effects?

#1 Most Reported
Product dose omission issue
363 reports (22.4%)
#2 Most Reported
Drug ineffective
223 reports (13.8%)
#3 Most Reported
Psoriasis
86 reports (5.3%)

All TILDRAKIZUMAB-ASMN Side Effects by Frequency

Side Effect Reports % of Total Deaths Hosp.
Product dose omission issue 363 22.4% 4 10
Drug ineffective 223 13.8% 0 2
Psoriasis 86 5.3% 0 3
Death 84 5.2% 84 1
Product storage error 74 4.6% 0 0
Self-medication 74 4.6% 0 0
Off label use 66 4.1% 2 0
Condition aggravated 63 3.9% 0 2
Rash 54 3.3% 1 1
Pruritus 52 3.2% 0 1
Therapy cessation 50 3.1% 0 3
Inappropriate schedule of product administration 41 2.5% 0 2
Diarrhoea 36 2.2% 0 3
Circumstance or information capable of leading to medication error 35 2.2% 0 0
Product administration error 24 1.5% 0 1
Therapeutic response decreased 24 1.5% 0 0
Disease recurrence 23 1.4% 0 0
Pain 23 1.4% 0 3
Arthralgia 22 1.4% 0 0
Therapy interrupted 17 1.1% 1 0

Who Reports TILDRAKIZUMAB-ASMN Side Effects? Age & Gender Data

Gender: 53.8% female, 46.2% male. Average age: 63.8 years. Most reports from: US. View detailed demographics →

Is TILDRAKIZUMAB-ASMN Getting Safer? Reports by Year

YearReportsDeathsHosp.
2015 1 0 0
2017 2 0 2
2018 2 0 2
2019 36 0 3
2020 34 4 3
2021 39 2 9
2022 47 0 8
2023 56 5 4
2024 68 14 6
2025 48 15 5

View full timeline →

What Is TILDRAKIZUMAB-ASMN Used For?

IndicationReports
Psoriasis 879
Product used for unknown indication 691
Psoriatic arthropathy 19

TILDRAKIZUMAB-ASMN vs Alternatives: Which Is Safer?

TILDRAKIZUMAB-ASMN vs TILIDINE TILDRAKIZUMAB-ASMN vs TIMOLOL TILDRAKIZUMAB-ASMN vs TIMOLOL\TRAVOPROST TILDRAKIZUMAB-ASMN vs TINIDAZOLE TILDRAKIZUMAB-ASMN vs TINZAPARIN TILDRAKIZUMAB-ASMN vs TIOCONAZOLE TILDRAKIZUMAB-ASMN vs TIOPRONIN TILDRAKIZUMAB-ASMN vs TIOTROPIUM TILDRAKIZUMAB-ASMN vs TIPIRACIL\TRIFLURIDINE TILDRAKIZUMAB-ASMN vs TIPRANAVIR

Official FDA Label for TILDRAKIZUMAB-ASMN

Official prescribing information from the FDA-approved drug label.